KNK437 Heat Shock Protein Inhibitor I|cas:218924-25-5|西域试剂

KNK437 Heat Shock Protein Inhibitor I,98.03%

产品编号：Bellancom-100110| CAS NO：218924-25-5| 分子式：C₁₃H₁₁NO₄| 分子量：245.23

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100110	￥600.00	杭州北京（现货）
Bellancom-100110	￥860.00	杭州北京（现货）
Bellancom-100110	￥1800.00	杭州北京（现货）
Bellancom-100110	￥3000.00	杭州北京（现货）
Bellancom-100110	￥5200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

KNK437 Heat Shock Protein Inhibitor I

产品介绍

KNK437 是 HSP 抑制剂，能够抑制 HSP105，HSP70 和 HSP40 的活化。

生物活性

KNK437 is a HSP inhibitor, and inhibits the induction of HSP105, HSP70, and HSP40.

体外研究

KNK437 inhibits the activation of several HSPs including HSP105, HSP70, and HSP40 in COLO 320DM (human colon carcinoma) cells. KNK437 (100 μM) inhibits thermotolerance in COLO 320DM cells after the first heat treatment. KNK437 shows inhibitory effects on thermotolerance dose-dependently in COLO 320DM cells (0-200 μM) and HeLa S3 cells (100, 200 μM). KNK437 (100 μM) exhibits inhibitory activities against the methylation of H3-Lys4 before or after heat-treatment in HSC4 cells and KB cells, but does not affect that of H3 Lys9. KNK437 also suppresses the expression of HSP70.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

KNK437 is a weakly toxic agent. KNK437 (62.5-400 mg/kg) recovers bodyweight losses of tumor-free CD-1 (ICR) mice. KNK437 (200 mg/kg) alone shows no antitumor effects and does not increase the thermosensitivity of nontolerant tumors. KNK437 improves the antitumor effects of fractionated heat treatment at 44°C at 200 mg/kg in a synergistic manner. KNK437 (200 mg/kg, i.p.) suppresses the induction of thermotolerance when administrated 6 h before the initial heating.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 31.25 mg/mL (127.43 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.0778 mL	20.3890 mL	40.7780 mL
5 mM	0.8156 mL	4.0778 mL	8.1556 mL
10 mM	0.4078 mL	2.0389 mL	4.0778 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 1.67 mg/mL (6.81 mM); Suspended solution; Need ultrasonic

此方案可获得 1.67 mg/mL (6.81 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液